-
Research progress of ultrasound-responsive drug release and drug activation strategies in cancer therapy
Time of Update: 2022-01-24
Andreas Herrmann from the Leibniz Institute for Materials Research in Germany published a review titled "Ultrasound-controlled drug release and drug activation for cancer therapy" on Exploration, and was selected as Inside Front Cover .
-
[Nature sub-issue] Too cunning, "anti-cancer magic drug" PARP inhibitor can also allow cancer cells to escape! Research reveals the secret of how cancer cells resist targeted therapy
Time of Update: 2022-01-24
Excitingly, this study shows that drugs currently used to treat alcohol addiction can be combined with PARP inhibitors to make the treatment of breast cancer caused by a mutated BRCA gene more effective .
-
Highlights of CStone's sugalimab in the treatment of stage III/IV NSCLC concurrently published in "The Lancet-Oncology"
Time of Update: 2022-01-24
Yimaike's recent hot reports ★CStone Pharmaceuticals and Hengrui Medicine reached a strategic cooperation of 1. 3 billion yuan to accelerate the development and commercialization of tumor immune skel
-
Eli Lilly's Abecili Tablets Adds Indications, Opening a New Era of Early Breast Cancer Treatment
Time of Update: 2022-01-24
That is, abeccil tablets combined with endocrine therapy (tamoxifen or aromatase inhibitor) as adjuvant therapy are suitable for hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, lymph node positive, high Adult patients with early-stage breast cancer at risk of recurrence and Ki-67 ≥20% .
-
Prodrugs for diagnosis and treatment enable precise treatment of cancer
Time of Update: 2022-01-24
As shown in Figure 3, the researchers used the prepared diagnostic prodrug NMAC4A-CyNH2 to visually monitor the release of drug molecule NM in tumor cells by laser confocal microscopy .
-
Research in the field of urothelial cancer in China: 2021 transcript
Time of Update: 2022-01-24
During the "2022 Beijing Urinary Oncology Youth Forum", Professor Zhang Cuijian of Peking University First Hospital shared the published articles of Chinese researchers in the field of urothelial cancer (bladder cancer and upper urinary tract urothelial cancer) in 2021.
-
The third-generation CD20 monoclonal antibody, Rituxi Dugu, who has been fighting for more than 20 years
Time of Update: 2022-01-24
In the lymphoma treatment recommendations of the CSCO (China Anti-Cancer Association Clinical Oncology Collaborative Professional Committee) authoritative guideline, rituximab is used in many lymphoma types, including diffuse large B-cell lymphoma, follicular lymphoma, mantle Cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, etc.
-
Express significantly reduces the risk of recurrence after lung cancer surgery, and Keytruda is expected to benefit patients at an earlier stage
Time of Update: 2022-01-24
The trial met one of its dual primary endpoints in patients with stage IB-IIIA non-small cell lung cancer (NSCLC), regardless of PD-L1 expression, who underwent surgical resection with Keytruda compared with placebo.
-
Academician Martin: The progress of gynecological oncology research in 2021 is encouraging, but the disappointments still need to be explored
Time of Update: 2022-01-24
In 2021, significant progress will be made in the treatment of ovarian, cervical, endometrial and trophoblastic cancers . "NEJM Medical Frontier" invited Academician Martin of Tongji Hospital Affili
-
Super hot target CD47/SIRPα!
Time of Update: 2022-01-24
(“Borui Bio”) announced its self-developed humanized monoclonal antibody BR105 injection targeting SIRPα The clinical trial application for oncology treatment was approved by the National Medical Products Administration (NMPA) .
-
60+ Reviews Take You To Learn About Fatty Acids In Cancer
Time of Update: 2022-01-24
Function of fatty acids in cancer cells Given the complex role of lipids in cellular physiology, it is clear , dysregulated FA synthesis must lead to cancer at many levels, including not only the production of building blocks for membrane synthesis during cell growth or the provision of substrates for ATP synthesis (BOX 1 ) and the regulation of signaling pathways involved in cell proliferation and survival .
-
mRNA delivery facilitates new breakthroughs in CAR-M therapy, Moderna changes the game rules of solid tumor therapy, Yimaimeng broke the news
Time of Update: 2022-01-24
" CAR-M Therapeutics - A New Approach to Treating Solid Tumors CAR (Chimeric Antigen Receptor) technology is a perfect fusion of genetic engineering and immunotherapy, and is one of the most promising research directions in the current field of tumor treatment .
-
Yao Qinghua and other CN heavyweights: Nutrition is the key!
Time of Update: 2022-01-24
1- National quintessence dedication! The latest research by the Chinese scientific research team found that the traditional Chinese medicine Papusan relieves colitis by regulating intestinal flora an
-
SIBIMAN’s CD19/CD20 CAR-T cell therapy has been granted RMAT and Fast Track dual qualifications by the FDA
Time of Update: 2022-01-24
S. Food and Drug Administration (FDA) awarded the Company Cellular Therapeutic product C-CAR039 (a novel autologous bispecific CAR-T therapy targeting CD19 and CD20 antigens) regenerative medicine advanced therapy (RMAT) qualification and fast track (FT) qualification for the treatment of relapsed or refractory and diffuse large B-cell lymphoma (r/r DLBCL) .
-
Nature sub-journal: Soochow University Wang Chao/Chen Jingrun and others develop yeast cell wall nanoparticles to enhance cancer treatment effect
Time of Update: 2022-01-24
Next, we explored the effect of yeast cell wall-derived nanoparticles on the immunosuppressive tumor microenvironment (TME), which showed that these nanoparticles significantly inhibited the growth of B16-luc tumors, among which, small-sized nanoparticles exhibited the greatest antitumor effect.
Among them, small-sized yeast cell wall-derived nanoparticles significantly inhibited tumor growth by remodeling the immunosuppressive microenvironment in tumors and tumor-draining lymphocytes.
-
Prof. Fan Lei: The best immunotherapy predictor for TNBC remains to be explored, and precision treatment is imperative 2021 SABCS Review and Reflections
Time of Update: 2022-01-24
First randomized, placebo-controlled phase III study of bolizumab as neoadjuvant and adjuvant therapy in early-stage TNBC, based on significant event-free survival (EFS) and pathological complete response (pCR) benefits, USA The Food and Drug Administration (FDA) approved pembrolizumab + chemotherapy neoadjuvant therapy, and continued pembrolizumab postoperative adjuvant therapy for early-stage high-risk TNBC patients .
-
Prof. Tao Wang: New research on new drugs has come out, consolidating the evidence of evidence-based medicine, and reviewing and prospecting the progress of adjuvant therapy for breast cancer
Time of Update: 2022-01-24
The Monarch E study showed that the addition of a "targeted drug" CDK4/6 inhibitor (abecili) on the basis of the original standard endocrine therapy in high-risk HR-positive breast cancer patients can improve disease-free survival (DFS) and long-term maintain efficacy .
-
The "Reaper" vaccine received a special evaluation agreement from the US FDA, which is expected to extend the recurrence-free survival period.
Time of Update: 2022-01-24
S. FDA for a cancer vaccine for the treatment of melanoma The pivotal Phase III clinical study of seviprotimut-L reached an agreement for the adjuvant treatment of stage IIB or IIC melanoma patients aged 60 years and older after definitive surgical resection to improve recurrence-free survival (RFS) .
-
JPM2022: Ready to go, the legendary creature BCMA CAR-T is about to enter the runway, Yi Mai Meng broke the news
Time of Update: 2022-01-24
If cilta-cel is finally approved by the FDA, it is expected to become the second CAR-T cell therapy targeting BCMA in the world, which will bring new options for the treatment of r/r MM .
-
BMC Cancer: Eribulin improves overall survival after initiation of first-line chemotherapy in patients with HER2-negative advanced breast cancer
Time of Update: 2022-01-23
Studies have shown that Eribulin improves overall survival after the initiation of first-line chemotherapy in patients with HER2-negative advanced breast cancer .
Studies have shown that Eribulin improves overall survival after the initiation of first-line chemotherapy in patients with HER2-negative advanced breast cancer .
